The fundamental goal of the proposed Washington University/Siteman Cancer Center (WU/SCC) Lead Academic Site is to create a supportive environment that will foster 1) scientific leadership and mentorship, 2) development of cooperative group clinical trials, 3) substantial accrual to clinical trials across the entire NCTN and 4) exceptional conduct of clinical trials. Investigators at WU/SCC are committed to work to enhance the research goals of the NCTN Program and to enroll patients to NCTN trials across the Network. WU/SCC investigators have a long history of enthusiastic participation in the cooperative groups including ACOSOG, ACRIN, CALGB, GOG, and RTOG and will continue to play key roles in the newly merged groups including the Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group, and NRG Oncology. WU/SCC will have 5 U10 Principal Investigators comprising the senior leadership team including Nancy L. Bartlett, MD (Professor, Medical Oncology), Bryan F. Meyers, MD, MPH (Professor, Thoracic Oncology), Jeff M. Michalski, MD, MBA (Professor, Radiation Oncology), David G. Mutch, MD (Professor, Gynecologic Oncology) and Barry A. Siegel, MD (Professor, Radiology). All members of the senior leadership team have extensive clinical trial experience, including many years of cooperative group involvement, and are committed to providing guidance for an institution-wide cooperative group NCTN UI0. WU/SCC is consistently among the top accruing institutions in each of the cooperative groups with outstanding accrual across many disease sites. Between January 2007 and June 2012, WU/SCC accrued 1633 patients to cooperative group therapeutic trials, an average of 297 patients per year for the last 5.5 years (171 ACOSOG, 1024 CALGB/Alliance, 156 GOG, and 282 RTOG). During this same interval, 727 patients had biospecimens collected and 101 patients were accrued to advanced imaging studies through ACRIN. WU/SCC investigators are highly motivated to contribute to the scientific mission of the NCTN, particularly in the areas of breast cancer, gynecological oncology, thoracic oncology, Gl oncology, GU oncology, leukemia, and lymphoma. Strong translational science in breast cancer, lung cancer, and AML at WU/SCC, along with large institutional biorepositories, will provide many opportunities for unique contributions to correlative studies associated with cooperative group therapeutic trials. This institution-wide UIO will facilitate enhanced communication and collaboration among disease site and modality specialists and improve our potential for contributions to the NCTN operation.

Public Health Relevance

SCC is the only NCI-designated Comprehensive Cancer Center in Missouri or Southern Illinois and it is the leading oncology treatment facility within th St. Louis metropolitan area. Participation in the NCTN allows WU/SCC physicians to offer a broad range of clinical trials to patients with all types and stages of cancer and also provides an opportunity for investigators to confirm preliminary institutional findings regarding new cancer treatments, diagnostic tools, and prognostic markers in large numbers of patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA180833-03
Application #
9031085
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
2014-05-02
Project End
2019-02-28
Budget Start
2016-03-01
Budget End
2017-02-28
Support Year
3
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Washington University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Henke, L E; Contreras, J A; Green, O L et al. (2018) Magnetic Resonance Image-Guided Radiotherapy (MRIgRT): A 4.5-Year Clinical Experience. Clin Oncol (R Coll Radiol) 30:720-727
Felix, A S; Brasky, T M; Cohn, D E et al. (2018) Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study. Int J Cancer 142:1102-1115
Tanioka, Maki; Fan, Cheng; Parker, Joel S et al. (2018) Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clin Cancer Res 24:5292-5304
Tallarico, Michael; Foster, Jared C; Seisler, Drew et al. (2018) Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611). J Geriatr Oncol 9:321-328
McCleary, Nadine J; Hubbard, Joleen; Mahoney, Michelle R et al. (2018) Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). J Geriatr Oncol 9:24-31
Woyach, Jennifer A; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med 379:2517-2528
Gounder, Mrinal M; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Sorafenib for Advanced and Refractory Desmoid Tumors. N Engl J Med 379:2417-2428
King, Rebecca L; Nowakowski, Grzegorz S; Witzig, Thomas E et al. (2018) Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era. Blood Cancer J 8:27
Le Gallo, Matthieu; Rudd, Meghan L; Urick, Mary Ellen et al. (2018) The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas. Cancer 124:65-73
Cosgrove, Casey M; Tritchler, David L; Cohn, David E et al. (2018) An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. Gynecol Oncol 148:174-180

Showing the most recent 10 out of 121 publications